ArticleScientific reports2026
ARL13B is regulated by the ERK/P90 pathway and mediates TMZ resistance in glioblastoma via microvesicles.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Temozolomide (TMZ) resistance presents a serious challenge in glioma treatment. It has been revealed that high expression of ADP-ribosylation factor-like GTPase 13B (ARL13B) is an important risk factor for glioma patients and is strongly related to RHO GTPase. Here, we presented a unique mechanism by which ARL13B induces TMZ resistance. The TCGA and CGGA datasets were used to conduct survival analysis. Metascape was utilized to perform pathway enrichment analysis. Western blot (WB), nanoparticle tracking analysis (NTA), and liquid chromatography-mass spectrometry (LC-MS) were used to explore the mechanisms of drug vesicular exocytosis that leads to ARL13B-mediated TMZ resistance. WB, qRT-PCR, and ChIP were used to validate the extracellular-regulated kinase (ERK)/P90 transcriptional regulatory signaling pathways. The expression of ARL13B increased ectosome efflux and decreased intracellular drug concentration. Besides, the ERK/P90 pathway could transcriptionally regulate ARL13B with C/EBPβ being one of the transcription factors of ARL13B. Inhibiting the ERK/P90 pathway could enhance the efficacy of TMZ. ARL13B was regulated by the ERK/P90 pathway and might impair the efficacy of TMZ by increasing drug efflux through ectosomes. Therefore, our study provided a novel mechanism of TMZ resistance and identifies a new target for glioma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.